MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited General and Administrative Expenses 2011-2026 | VNRX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.49 M | 10.4 M | 10.2 M | 11.7 M | 5.47 M | 4.52 M | 5.78 M | 5.36 M | 5.43 M | 3.9 M | 1.91 M | 1.72 M | 1.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.7 M | 1.3 M | 5.85 M |
Quarterly General and Administrative Expenses VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.48 M | 2.94 M | 2.24 M | - | 1.82 M | 2.28 M | 2.25 M | - | 2.6 M | 2.64 M | 2.58 M | - | 2.76 M | 3.09 M | 2.6 M | - | 3.14 M | 2.43 M | 1.81 M | - | 1.08 M | 1.51 M | 1.7 M | - | 1.35 M | 1.44 M | 1.23 M | - | 1.45 M | 1.64 M | 1.84 M | - | 1.56 M | 1.43 M | 1.4 M | - | 164 K | 166 K | 228 K | - | 141 K | 122 K | 248 K | - | 129 K | 51.8 K | 68.9 K | - | 68 K | 123 K | 51.6 K | - | 48.2 K | 149 K | 38 K | - | 54.7 K | 45.1 K | 49.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.14 M | 38 K | 1.27 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
6.63 M | $ 2.83 | -4.25 % | $ 91.8 K |  USA |
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.62 B | $ 116.73 | -1.22 % | $ 35.5 B | USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 27.49 | -1.8 % | $ 764 M | USA |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 13.85 | -2.46 % | $ 419 M | USA |
 |
Celcuity
CELC
|
9.06 M | $ 106.91 | -1.28 % | $ 4.22 B | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 105.19 | -2.84 % | $ 8.68 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
405 M | $ 632.07 | -0.73 % | $ 50.8 B | USA |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Illumina
ILMN
|
1.09 B | $ 129.42 | -2.61 % | $ 20.6 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
743 M | $ 174.37 | -2.39 % | $ 8.64 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 281.25 | -1.82 % | $ 23.4 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 76.52 | 0.29 % | $ 5.16 B | USA |
 |
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 305.65 | -1.47 % | $ 26.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.93 | -1.58 % | $ 457 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M |  China |
 |
NeoGenomics
NEO
|
273 M | $ 9.21 | -3.05 % | $ 1.18 B | USA |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
Natera
NTRA
|
589 M | $ 204.79 | 2.31 % | $ 20.2 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 1.51 | -7.1 % | $ 453 M | USA |
|
Biodesix
BDSX
|
80.5 M | $ 16.06 | 1.94 % | $ 2.08 B | USA |
 |
Precipio
PRPO
|
9.45 M | $ 24.5 | -0.73 % | $ 31.8 M | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
51.9 M | $ 1.1 | -3.51 % | $ 1.4 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 206.91 | -1.59 % | $ 23 B | USA |
 |
Danaher Corporation
DHR
|
8.24 B | $ 201.42 | -2.22 % | $ 144 B | USA |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 7.55 | -8.85 % | $ 315 M | USA |
 |
Sotera Health Company
SHC
|
253 M | $ 15.64 | -1.69 % | $ 4.44 B | USA |
 |
Soleno Therapeutics
SLNO
|
132 M | $ 37.95 | -2.84 % | $ 1.93 B | USA |
 |
Exact Sciences Corporation
EXAS
|
889 M | $ 103.38 | 0.03 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
304 M | $ 8.66 | -1.25 % | $ 543 M | USA |
 |
DarioHealth Corp.
DRIO
|
18.1 M | $ 10.5 | -2.33 % | $ 298 M |  Israel |
 |
DexCom
DXCM
|
1.29 B | $ 72.73 | -1.42 % | $ 28.4 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.73 B | $ 503.03 | -1.07 % | $ 190 B | USA |
 |
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
490 M | $ 24.2 | -5.62 % | $ 258 M | China |
 |
Twist Bioscience Corporation
TWST
|
247 M | $ 45.21 | -1.48 % | $ 2.7 B | USA |
 |
CareDx, Inc
CDNA
|
108 M | $ 18.36 | -2.08 % | $ 978 M | USA |
 |
Waters Corporation
WAT
|
240 M | $ 305.23 | -0.62 % | $ 18.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | Israel |
 |
Guardant Health
GH
|
211 M | $ 91.08 | -1.25 % | $ 11.4 B | USA |
 |
IQVIA Holdings
IQV
|
2 B | $ 171.57 | -1.55 % | $ 29.5 B | USA |